Webinar Recordings

From Target Discovery to Toxicology: Combining Cell Painting and Transcriptomics Across the Drug Discovery Workflow

How much more can you learn from every screening plate? In this joint webinar, Roberto Ravasio (Principal Scientist, Axxam) and Riccardo Dainese (CBO and co-founder, Alithea Genomics) show how Cell Painting and MERCURIUS™ DRUG-seq work together across the drug discovery workflow, with real data from two case studies.

How much more can you learn from every screening plate? In this joint webinar, Roberto Ravasio (Principal Scientist, Axxam) and Riccardo Dainese (CBO and co-founder, Alithea Genomics) show how Cell Painting and MERCURIUS™ DRUG-seq work together across the drug discovery workflow, with real data from two case studies.

Case study 1 – Target validation in human iPSC-derived motor neurons
An arrayed CRISPR screen of 90 ALS-relevant targets under arsenite stress, profiled with Cell Painting and DRUG-seq. Integrating both readouts at target level puts SMARCA4 and HDAC6 among the top candidates for follow-up.

Case study 2 – Which readout flags liver toxicity first?
58 drugs from the FDA DILIrank dataset, 8 doses each, in HepaRG and U2OS cells: 2,160 samples per readout and cell model. DRUG-seq names the mechanism (DNA damage, mitochondrial stress) and Cell Painting shows its effect on the cell.

What you will learn

  • Where Cell Painting and transcriptomics fit from target identification to safety
  • How two readouts on the same plates build a stronger case for each target
  • How DRUG-seq pinpoints the mechanism and the dose at which it switches on
  • How gene-level benchmark dose modelling detects activation at lower doses

Chapters


0:00 Welcome and speakers
0:50 Agenda
1:33 Why combine readouts? Better perturbation data for AI-driven drug discovery
3:29 Alithea Genomics and MERCURIUS™ DRUG-seq
7:07 Axxam: science-driven drug discovery
9:43 Cell Painting + DRUG-seq: one workflow, two readouts
11:53 Case study 1: target validation in iPSC-derived motor neurons (ALS)
18:26 Cell Painting results: six phenotypic programs
22:40 Adding DRUG-seq: ALS-relevant transcriptional programs
24:48 Integrated target prioritization: SMARCA4 and HDAC6
30:34 Case study 2: which readout flags liver toxicity first?
32:05 Point of departure: Cell Painting vs DRUG-seq
35:53 Mechanisms: DNA damage and mitochondrial toxicity
38:56 Glitazones: shared target, distinct phenotypes
41:41 Benchmark dose modelling with DRUG-seq
43:29 Takeaways
45:27 Q&A: comparison with the JUMP Consortium
47:30 Q&A: Cell Painting image analysis at Axxam
48:58 Q&A: knockout efficiency in iPSC-derived neurons
50:24 Q&A: estimating a therapeutic window
53:42 Q&A: recovering mechanisms of action
55:42 Q&A: how many cell types for toxicity screening?

Speakers

Riccardo Dainese

CBO and co-founder

Riccardo is the CBO and co-founder of Alithea Genomics.

Before that, he completed his PhD in Bioengineering and Microfluidics at the Swiss Federal Institute of Technology (EPFL) in the Laboratory of Systems Biology and Genetics run by Prof. Bart Deplancke.

During his PhD Riccardo has worked on and co-developed a number of microvalve-based and droplet-based microfluidic devices with genomic applications, such as Smile-seq, FloChIP, DisCO all of which have been patented separately and published in top-tier journals such as Nature Methods and PNAS.

Before his PhD, Riccardo obtained a Master’s degree in Nanotechnology at Chalmers University (Goteborg, Sweden) and a Bachelor’s in Biomedical Engineering at the Politecnico di Torino (Italy).

Roberto Ravasio

Principal Scientist

Roberto Ravasio is Principal Scientist in the Advanced Cellular Assay group at Axxam, where he leads multidisciplinary drug discovery projects for biotech and pharmaceutical partners. His expertise spans cell and molecular biology, functional genomics, molecular assay development, and phenotypic and omics-based profiling, with a particular focus on Cell Painting and transcriptomics. By integrating complementary technologies and multidimensional datasets, his work supports target discovery and validation, compound profiling, and in vitro preclinical safety assessment, translating complex biological readouts into actionable insights across the drug discovery workflow.

Roberto obtained his BSc and MSc from the University of Milan and completed his PhD and postdoctoral research at the European Institute of Oncology in Milan, where he focused on functional genomics and omics approaches for drug discovery and translational research.

Ready to talk about your next RNA-seq study?

Tell us about your project and we will help you find the right approach.